Overview

Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Determine the effect of treatment with INCB013739 administered as an 'add-on' to metformin therapy in type 2 diabetic subjects on safety and tolerability and glycemic control.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation
Treatments:
Metformin